PENDING IPRs
Rituxan® (Rituximab)
- IPR2016-01614
- Patent Number: 7,820,161
- Patent Owner: Biogen, inc.
- Petitioner: Celltrion, Inc.
- Status: Institution decision pending
- Petition
Patent Owner Preliminary Response (None filed)
Decision on Institution
- IPR2016-01667
- Patent Number: 7,976,838
- Patent Owner: Genentech, Inc.
- Petitioner: Celltrion, Inc.
- Status: Institution Denied
- Petition
Patent Owner Preliminary Response
Decision Denying Institution
- IPR2017-01093
- Patent Number: 8,329,172
- Patent Owner: Biogen
- Petitioner: Celltrion
- Status: Institution Decision Pending
- Petition
- IPR2017-01094
- Patent Number: 8,557,244
- Patent Owner: Biogen
- Petitioner: Celltrion
- Status: Institution Decision Pending
- Petition
- IPR2017-01095
- Patent Number: 9,296,821
- Patent Owner: Biogen
- Petitioner: Celltrion
- Status: Institution Decision Pending
- Petition
- IPR2017-01227
- Patent Number: 7,682,612
- Patent Owner: Genentech
- Petitioner: Celltrion
- Status: Institution Decision Pending
- Petition
- IPR2017-01229
- Patent Number: 8,206,711
- Patent Owner: Genentech
- Petitioner: Celltrion
- Status: Institution Decision Pending
- Petition
- IPR2017-01230
- Patent Number: 7,682,612
- Patent Owner: Genentech
- Petitioner: Celltrion
- Status: Institution Decision Pending
- Petition
- IPR2017-01115
- Patent number: 7,820,161
- Patent Owner: Genentech
- Petitioner: Pfizer
- Status: Institution Decision Pending
- Petition
- IPR2017-01166
- Patent number: 8,329,172
- Patent Owner: Biogen, Inc.
- Petitioner: Pfizer
- Status: Institution Decision Pending
- Petition
- IPR2017-01167
- Patent number: 8,577,244
- Patent Owner: Biogen, Inc.
- Petitioner: Pfizer
- Status: Institution Decision Pending
- Petition
- IPR2017-01168
- Patent number: 8,821,873
- Patent Owner: Biogen, Inc.
- Petitioner: Pfizer
- Status: Institution Decision Pending
- Petition
Humira® (adalimumab)
- IPR2016-00408
- Patent number: 8,889,135
- Patent owner: AbbVie Biotechnology Ltd.
- Petitioner: Boehringer Ingelheim Pharmaceuticals, Inc.
- Status: Trial Instituted
- Petition
Patent Owner Preliminary Response
Decision on Institution
Patent Owner Response
Petitioner Reply
- IPR2016-00409
- Patent number: 8,889,135
- Patent owner: AbbVie Biotechnology Ltd.
- Petitioner: Boehringer Ingelheim Pharmaceuticals, Inc.
- Status: Trial Instituted
- Petition
Patent Owner Preliminary Response
Decision on Institution
Patent Owner Response
Petitioner Reply
- IPR2016-00172
- Patent number: 8,889,135
- Patent owner: AbbVie Biotechnology Ltd.
- Petitioner: Coherus BioSciences Inc.
- Status: Trial Instituted
- Petition
Patent Owner Preliminary Response
Decision on Institution
Patent Owner Response
Petitioner’s Reply
Petitioner’s Revised Reply
- IPR2016-00188
- Patent number: 9,017,680
- Patent owner: AbbVie Biotechnology Ltd.
- Petitioner: Coherus BioSciences Inc.
- Status: Trial Instituted
- Petition
Patent Owner Preliminary Response
Decision on Institution
Patent Owner Response
Petitioner’s Reply
Petitioner’s Revised Reply
- IPR2016-00189
- Patent number: 9,073,987
- Patent owner: AbbVie Biotechnology Ltd.
- Petitioner: Coherus BioSciences Inc.
- Status: Trial Instituted
- Petition
Patent Owner Preliminary Response
Decision on Institution
Patent Owner Response
Petitioner’s Reply
Petitioner’s Revised Reply
- IPR2017-00823
- Patent number: 9,085,619
- Patent Owner: AbbVie Biotechnology, Ltd.
- Petitioner: Coherus BioSciences Inc.
- Status: Institution decision pending
- Petition
Replacement Petition
- IPR2017-00822
- Patent number: 9,085,619
- Patent Owner: AbbVie Biotechnology, Ltd.
- Petitioner: Coherus BioSciences, Inc.
- Status: Institution decision pending
- Petition
Replacement Petition
- IPR2017-00826
- Patent number: 9,085,619
- Patent Owner: AbbVie Biotechnology, Ltd.
- Petitioner: Coherus BioSciences, Inc.
- Status: Institution decision pending
- Petition
- IPR2017-00827
- Patent number: 9,085,619
- Patent Owner: AbbVie Biotechnology, Ltd.
- Petitioner: Coherus BioSciences, Inc.
- Status: Institution decision pending
- Petition
- IPR2017-01008
- Patent number: 9,085,619
- Patent Owner: AbbVie Biotechnology, Ltd.
- Petitioner: Coherus BioSciences, Inc.
- Status: Institution decision pending
- Petition
- IPR2017-01009
- Patent number: 9,085,619
- Patent Owner: AbbVie Biotechnology, Ltd.
- Petitioner: Coherus BioSciences, Inc.
- Status: Institution decision pending
- Petition
General Biologic Patents
- IPR2016-01608
- Patent number: 6,716,602
- Patent Owner: Genentech
- Petitioner: bioeq
- Status: Institution Denied
- Petition
Patent Owner Preliminary Response
Petitioner’ Reply to Patent Owner Preliminary Response
Decision Denying Institution
- IPR2016-00258
- Patent number: 9,051,556
- Patent owner: Shire
- Petitioner: Green Cross Corp.
- Status: Trial Instituted
- Petition
Patent Owner Preliminary Response
Decision on Institution
Final Written Decision
- IPR2017-01129
- Patent number: 8,679,487
- Patent Owner: Immunex Corp.
- Petitioner: Sanofi-Aventis, Genzyme, and Regeneron
- Status: Institution Decision Pending
- Petition
- IPR2017-01252
- Patent number: 6,946,292
- Patent Owner: Kyowa Kakko Kirin Co., Ltd.
- Petitioner: Aragen Bioscience, Inc.
- Status: Institution Decision Pending
- Petition
- IPR2017-01254
- Patent number: 8,067,232
- Patent Owner: Kyowa Hakko Kirin Co., Ltd.
- Petitioner: Aragen Bioscience, Inc.
- Status: Institution Decision Pending
- Petition
- IPR2017-01262
- Patent number: 7,425,446
- Patent Owner: Kyowa Hakko Kirin Co., Ltd.
- Petition: Aragen Bioscience, Inc.
- Status: Institution Decision Pending
- Petition
Cabilly Patents
- IPR2016-01373
- Patent number: 6,331,415
- Patent owner: Genentech
- Petitioner: Merck Sharp & Dohme Corporation
- Status: Institution denied
- Petition
Patent Owner Preliminary Response
Decision on Institution
- IPR2016-00710
- Patent number: 6,331,415
- Patent owner: Genentech, Inc.
- Petitioner: Mylan Pharmaceuticals Inc.
- Status: Trial Instituted
- Petition
Patent Owner Preliminary Response – None Filed
Decision on Institution
Patent Owner Response
Petitioner’s Reply
Termination Decision
- IPR2017-00047
- Patent number: 6,331,415
- Patent owner: Genentech, Inc.
- Petitioner: Merck Sharp and Dohme
- Status: Petition Instituted
- Petition
Decision on Institution
Neulasta (pegfilgrastim)
- IPR2016-01542
- Patent number: 8,952,138
- Patent Owner: Amgen
- Petitioner: Apotex
- Status: Instituted
- Petition
Patent Owner Preliminary Response
Institution Decision
Herceptin (trastuzumab)
- IPR2016-01693
- Patent number: 6,407,213
- Patent Owner: Genentech
- Petitioner: Mylan
- Status: Institution Decision Pending
- Petition
Patent Owner Preliminary Response
Termination Decision
- IPR2016-01694
- Patent number: 6,407,213
- Patent Owner: Genentech
- Petitioner: Mylan
- Status: Institution Decision Pending
- Petition
Patent Owner Preliminary Response
Termination Decision
- IPR2016-01837
- Patent number: 7,807,799
- Patent Owner: Genentech
- Petitioner: Hospira
- Status: Instituted
- Petition
Decision on Institution
- IPR2017-00739
- Patent number: 7,892,549
- Patent Owner: Genentech
- Petitioner: Hospira
- Status: Institution Decision Pending
- Petition
- Patent Owner Preliminary Response
- IPR2017-00737
- Patent number: 7,892,549
- Patent Owner: Genentech
- Petitioner: Hospira
- Status: Institution Decision Pending
- Petition
- Patent Owner Preliminary Response
- IPR2017-00731
- Patent number: 7,846,441
- Patent Owner: Genentech
- Petitioner: Hospira
- Status: Institution Decision Pending
- Petition
- Patent Owner Preliminary Response
- IPR2017-00805
- Patent number: 7,371,379
- Patent Owner: Genentech
- Petitioner: Hospira
- Status: Institution Decision Pending
- Petition
- Patent Owner Preliminary Response
- IPR2017-00804
- Patent number: 6,627,196
- Patent Owner: Genentech
- Petitioner: Hospira
- Status: Institution Decision Pending
- Petition
- Patent Owner Preliminary Response
- IPR2017-00959
- Patent number: 8,591,897
- Patent Owner: Genentech
- Petitioner: Celltrion
- Status: Institution Decision Pending
- Petition
- IPR2017-01121
- Patent number: 7,846,441
- Patent Owner: Genentech
- Petitioner: Celltrion
- Status: Institution Decision Pending
- Petition
- IPR2017-01122
- Patent number: 7,892,549
- Patent Owner: Genentech
- Petitioner: Celltrion
- Status: Institution Decision Pending
- Petition
- IPR2017-01139
- Patent number: 6,627,196
- Patent Owner: Genentech
- Petitioner: Celltrion
- Status: Institution Decision Pending
- Petition
- IPR2017-01140
- Patent number: 7,371,379
- Patent Owner: Genentech
- Petitioner: Celltrion
- Status: Institution Decision Pending
- Petition
Avastin (bevacizumab)
- IPR2016-01771
- Patent number: 7,622,115
- Patent Owner: Genentech
- Petitioner: Hospira
- Status: Instituted
- Petition
Decision on Institution
TERMINATED IPRS
Rituximab (Rituxan)
- IPR2015-00417
- Patent number: 7,976,838
- Patent owner: Genentech, Inc.
- Petitioner: Boehringer Ingelheim, Pharmaceuticals, Inc.
- Status: Terminated after institution following request for adverse judgment by petitioner
- Petition
Patent Owner Preliminary Response
Decision on Institution
- IPR2015-00415
- Patent number: 7,820,161
- Patent owner: Genentech, Inc.
- Petitioner: Boehringer Ingelheim Pharmaceuticals, Inc.
- Status: Terminated after institution following request for adverse judgment by petitioner
- Petition
Patent Owner Preliminary Response
Decision on Institution
- IPR2015-00418
- Patent number: 8,329,172
- Patent owner: Biogen, Inc.
- Petitioner: Boehringer Ingelheim Pharmaceuticals, Inc.
- Status: Denied institution
- Petition
Patent Owner Preliminary Response
Decision on Institution
- IPR2015-01744
- Patent number: 7,820,161
- Patent owner: Genentech, Inc.
- Petitioner: Celltrion
- Status: Terminated prior to institution following motion to dismiss by petitioner
- Petition
- IPR2015-01733
- Patent number: 7,976,838
- Patent owner: Genentech, Inc.
- Petitioner: Celltrion
- Status: Terminated prior to institution following motion to dismiss by petitioner
- Petition
Humira® (adalimumab)
- IPR2015-01514
- Patent number: 8,916,157
- Patent owner: AbbVie Biotechnology Ltd.
- Petitioner: Amgen Inc.
- Status: Institution denied
- Petition
Patent Owner Preliminary Response
Decision on Institution
- IPR2015-01517
- Patent number: 8,916,158
- Patent owner: AbbVie Biotechnology Ltd.
- Petitioner: Amgen Inc.
- Status: Institution denied
- Petition
Patent Owner Preliminary Response
Decision on Institution
- IPR2016- 01018
- Patent number: 9,114,166
- Patent owner: AbbVie Biotechnology Ltd.
- Petitioner: Coherus BioSciences Inc.
- Status: Institution denied
- Petition
Patent Owner Preliminary Response
Decision Denying Institution
Cabilly Patents
- IPR2016-00383
- Patent number: 6,331,415
- Patent owner: Genentech, Inc.
- Petitioner: Genzyme Corporation
- Status: Institution denied
- Petition
Patent Owner Preliminary Response
Decision on Institution
- IPR2015-01624
- Patent number: 6,331,415
- Patent owner: Genentech, Inc.
- Petitioner: Sanofi-Aventis U.S. LLC
- Status: Trial terminated following confidential settlement
- Petition
Patent Owner Preliminary Response
Decision on Institution
Patent Owner’s Response
Termination decision
- IPR2016-00460
- Patent number: 6,331,415
- Patent owner: Genentech, Inc.
- Petitioner: Genzyme Corporation
- Status: Trial terminated following confidential settlement
- Petition
Patent Owner Preliminary Response
Decision on Institution
Termination Decision
Enbrel® (etanercept)
- IPR2015-01792
- Patent number: 8,163,522
- Patent owner: Hoffman-LaRoche Inc.
- Petitioner: Coalition for Affordable Drugs V LLC
- Status: Institution denied
- Petition
Patent Owner Preliminary Response
Decision on Institution
Orencia® (abatacept)
- IPR2015-01537
- Patent number: 8,476,239
- Patent owner: Bristol-Myers Squibb Company
- Petitioner: Momenta Pharmaceuticals, Inc.
- Status: Patent Validity Upheld in FWD
- Petition
Patent Owner Preliminary Response
Decision on Institution
Patent Owner’s Response
Final Written Decision
Tysabri (natalizumab)
- IPR2016-00912
- Patent number: 8,815,236
- Patent owner: Biogen MA Inc.
- Petitioner: Swiss Pharma International AG
- Status: Institution denied – rehearing request pending
- Petition
Patent Owner Preliminary Response
Decision denying institution
- IPR2016-00915
- Patent number: 8,349,321
- Patent owner: Biogen MA Inc.
- Petitioner: Swiss Pharma International AG
- Status: Institution denied – rehearing request pending
- Petition
Patent Owner Preliminary Response
Decision denying institution
- IPR2016-00916
- Patent number: 8,900,577
- Patent owner: Biogen MA Inc.
- Petitioner: Swiss Pharma International AG
- Status: Institution denied – rehearing request pending
- Petition
Patent Owner Preliminary Response
Decision denying institution